Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Acerus Pharmaceuticals Corporation
  6. Summary
    ASP   CA00444G1081

ACERUS PHARMACEUTICALS CORPORATION

(ASP)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
04/16/2021 04/19/2021 04/20/2021 04/21/2021 04/22/2021 Date
0.055(c) 0.05(c) 0.055(c) 0.05(c) 0.05(c) Last
51 100 5 700 184 000 28 020 29 050 Volume
+10.00% -9.09% +10.00% -9.09% 0.00% Change
More quotes
Financials (USD)
Sales 2019 3,77 M - -
Net income 2019 -16,1 M - -
Net Debt 2019 14,7 M - -
P/E ratio 2019 -0,97x
Yield 2019 -
Sales 2020 1,09 M - -
Net income 2020 -24,4 M - -
Net cash position 2020 0,91 M - -
P/E ratio 2020 -1,05x
Yield 2020 -
Capitalization 61,5 M 61,5 M -
EV / Sales 2019 8,18x
EV / Sales 2020 43,7x
Nbr of Employees 10
Free-Float 8,36%
More Financials
Company
Acerus Pharmaceuticals Corporation, formerly Trimel Pharmaceuticals Corporation, is a Canada-based pharmaceutical company. The Company is engaged in the development, manufacture, marketing and distribution of products with a focus on men's health, including urology, and women's health, including hormone replacement therapy and female sexual dysfunction. The Company markets Estrace in Canada, which is an oral,... 
Sector
Pharmaceuticals
Calendar
05/17Earnings Release
More about the company
All news about ACERUS PHARMACEUTICALS CORPORATION
04/01ACERUS PHARMACEUTICALS  : Buys Back All Remaining U.S. Rights for NATESTO From A..
MT
04/01AYTU BIOPHARMA  : Sells US Rights to Low Testosterone Treatment Natesto to Aceru..
MT
04/01Acerus Buys Back All Remaining U.S. Rights for NATESTO® From Aytu
GL
03/30UPDATE : Acerus Pharmaceuticals Jumps 10% as Expands NATESTO Distribution to 20 ..
MT
03/30ACERUS PHARMACEUTICALS  : Expands NATESTO Distribution to 20 Countries
MT
03/30Acerus Announces Expansion of NATESTO® Distribution Worldwide
GL
03/26ACERUS PHARMACEUTICALS  : Amends Credit Agreement
MT
03/26Acerus Announces Amendment to Credit Agreement
GL
03/11Acerus Pharmaceuticals Reports Q4 Loss Per Share US$0.01
MT
03/11Acerus Reports Fourth Quarter and Full Year 2020 Financial Results
GL
03/11ACERUS : Q4 Earnings Snapshot
AQ
03/04ACERUS PHARMACEUTICALS  : to Report 2020 Financial Results and Host Investor Cal..
AQ
2020ACERUS PHARMACEUTICALS  : Near 52 Week Lows Announces Waiver of Q4 Financial Cov..
MT
2020ACERUS PHARMACEUTICALS  : Raises C$13.2 Million as It Wraps Up Rights Offering
MT
2020ACERUS PHARMACEUTICALS  : Announces Details of Previously Completed Rights Offer..
BU
More news
News in other languages on ACERUS PHARMACEUTICALS CORPORATION

- No features available -

More news
Chart ACERUS PHARMACEUTICALS CORPORATION
Duration : Period :
Acerus Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACERUS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Managers and Directors
NameTitle
Edward Gudaitis President, CEO & Non-Independent Director
Robert M. Motz Chief Financial Officer
Ian Orest Ihnatowycz Chairman
Christopher Sorli Chief Medical Officer
Stephen Gregory Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ACERUS PHARMACEUTICALS CORPORATION25.00%62
JOHNSON & JOHNSON4.96%438 583
ROCHE HOLDING AG2.64%298 619
PFIZER, INC.7.39%217 716
NOVARTIS AG-2.89%199 956
MERCK & CO., INC.-4.69%198 884